These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1703602)

  • 21. The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension.
    Panfilov V; Morris AD; Donnelly R; Scemama M; Reid JL
    Br J Clin Pharmacol; 1995 Dec; 40(6):563-9. PubMed ID: 8703663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Potassium channel activators. Perspectives in the treatment of arterial hypertension].
    Giudicelli JF; Richer C; Berdeaux A
    Presse Med; 1991 Jan; 20(2):75-81. PubMed ID: 1825708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular effects of the novel potassium channel opener UR-8225.
    Tamargo J; Pérez O; Delpón E; García-Rafanell J; Gómez L; Cavalcanti F
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):295-305. PubMed ID: 7475055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the haemodynamic profiles of Ro 31-6930, cromakalim and nifedipine in anaesthetised normotensive rats.
    Duty S; Paciorek PM; Waterfall JF; Weston AH
    Eur J Pharmacol; 1990 Aug; 185(1):35-42. PubMed ID: 2226633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.
    Cavero I; Mondot S; Mestre M
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemodynamic differences between cromakalim and pinacidil: comparison with nifedipine.
    Clapham JC; Longman SD
    Eur J Pharmacol; 1989 Nov; 171(1):109-17. PubMed ID: 2693121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of cromakalim on renal hemodynamics and function in dogs: comparison with nicardipine.
    Tamaki T; Hasui K; Shoji T; Fukui K; Iwao H; Abe Y
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):305-9. PubMed ID: 1709236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular pressor responses in treated and untreated essential hypertension.
    Donnelly R; Elliott HL; Howie CA; Sumner DJ; Reid JL
    J Cardiovasc Pharmacol; 1990 Aug; 16(2):191-6. PubMed ID: 1697373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo cardiac electrophysiologic effects of RWJ 29009, a new potassium-channel activator, in comparison to cromakalim and nicardipine.
    Damiano BP; Stump GL; Cheung WM; Salata JJ
    J Cardiovasc Pharmacol; 1993 Jul; 22(1):143-52. PubMed ID: 7690086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of cromakalim and nicorandil on intraocular pressure after topical administration in rabbit eyes.
    Chiang CH; Lin CH
    J Ocul Pharmacol Ther; 1995; 11(3):195-201. PubMed ID: 8590250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs.
    Kusumoto K; Awane Y; Kitayoshi T; Fujiwara S; Hashiguchi S; Terashita Z; Shiraishi M; Watanabe T
    J Cardiovasc Pharmacol; 1994 Dec; 24(6):929-36. PubMed ID: 7898076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cromakalim and cicletanine against pacing-induced myocardial ischemia in conscious rabbits.
    Szilvassy Z; Koltai M; Ferdinandy P; Jakab I; Lonovics J; Tarrade T; Allard M; Braquet PG
    Life Sci; 1994; 54(9):PL125-30. PubMed ID: 8114606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.
    Quast U; Cook NS
    J Pharmacol Exp Ther; 1989 Jul; 250(1):261-71. PubMed ID: 2501478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD; Clapham JC; Wilson C; Hamilton TC
    J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary vascular and renal effects of cromakalim in anaesthetized dogs.
    Hicks PE; Martin D; Dumez D; Zazzi-Sudriez E; Armstrong JM
    Pflugers Arch; 1989; 414 Suppl 1():S192-3. PubMed ID: 2780259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cromakalim, a potassium channel opener, on regional blood flow in conscious spontaneously hypertensive rats.
    Shoji T; Aki Y; Fukui K; Tamaki T; Iwao H; Abe Y
    Eur J Pharmacol; 1990 Sep; 186(1):119-23. PubMed ID: 2282933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats.
    Le Monnier de Gouville AC; Mondot S; Lippton H; Hyman A; Cavero I
    J Pharmacol Exp Ther; 1990 Jan; 252(1):300-11. PubMed ID: 2405151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.
    Baczkó I; Leprán I; Papp JG
    Eur J Pharmacol; 1997 Apr; 324(1):77-83. PubMed ID: 9137916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cromakalim does not protect against skeletal muscle fatigue in an anaesthetized rat model of acute hindlimb ischaemia.
    Trezise DJ; Drew GM; Roach AG; Watts IS; Weston AH
    Eur J Pharmacol; 1993 Nov; 250(1):109-16. PubMed ID: 8119308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
    Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
    Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.